Lisaftoclax vs Surzetoclax

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCL-2 · full Multiple Myeloma pipeline

Lisaftoclax

Marketed by Ascentage Pharma Group Inc.

Phase 1/2 in Multiple Myelomasmall molecule
Weak signal

NCT04674514 · Phase 1/2 · status unknown

This is a non-randomized, open-label dose-escalation study with no control group, primarily designed to establish a tolerable dose rather than to prove efficacy. Results have not yet been posted.

No aligned efficacy figure on record for this race.

Surzetoclax

Developed by AbbVie

Phase 1/2 in Multiple Myelomasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2030 · NCT06953960 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLisaftoclaxSurzetoclax
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

Lisaftoclax
—Not reported
Surzetoclax
—Not reported

OS, median

Lisaftoclax
—Not reported
Surzetoclax
—Not reported

ORR

Lisaftoclax
—Not reported
Surzetoclax
—Not reported

VGPR or better

Lisaftoclax
—Not reported
Surzetoclax
—Not reported

MRD negativity

Lisaftoclax
—Not reported
Surzetoclax
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Lisaftoclax: no structured comparison results are available for Multiple Myeloma.

Surzetoclax: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lisaftoclax's landscape · Surzetoclax's landscape